Dr Jake O'Donnell

Research Fellow

School of Chemistry and Molecular Biosciences
Faculty of Science


Research Interests

  • Monoclonal Antibody Development
    We have developed a pipeline for rapid flow cytometry and cell-sorting-based development of either mouse or human monoclonal antibodies with potential uses as research tools or therapies.
  • Human T-lymphotropic virus 1 (HTLV-1) and Adult T cell Leukemia/Lymphoma (ATLL)
    We have interests in the development of therapies for treatment of HTLV-1 and ATLL using basic research principles and structural biological approaches.
  • Understanding the impacts of vaccine adjuvants on immune responses
    We have interests in characterising the impacts that specific antigen/adjuvant pairings have in vaccine development, and how this understanding can guide adjuvant selection in vaccine development
  • The structural basis for anti-retroviral efficacy for novel indications
    We have interest in understanding the applicability and potential efficacy of existing and novel anti-retroviral therapies for treatment of different retroviral infections. Our current focuses are on HTLV-1 and Koala Retrovirus.


  • Doctor of Philosophy, The University of Queensland
  • Bachelor of Biomedical Science (Honours), The University of Queensland


View all Publications


Journal Article

  • O'Donnell, Jake S, Hunt, Stewart K and Chappell, Keith J (2023). Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma. The Lancet Haematology, 10 (7), e539-e548. doi: 10.1016/S2352-3026(23)00087-X

  • O’Donnell, Jake S., Isaacs, Ariel, Jakob, Virginie, Lebas, Celia, Barnes, James B., Reading, Patrick C., Young, Paul R., Watterson, Daniel, Dubois, Patrice M., Collin, Nicolas and Chappell, Keith J. (2022). Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine. Frontiers in Immunology, 13 976968. doi: 10.3389/fimmu.2022.976968

  • O’Donnell, Jake S. and Chappell, Keith J. (2021). Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?. Frontiers in Microbiology, 12 724654, 1-4. doi: 10.3389/fmicb.2021.724654

  • Lepletier, Ailin, Madore, Jason, O'Donnell, Jake S., Johnston, Rebecca L., Li, Xian-Yang, McDonald, Elizabeth, Ahern, Elizabeth, Kuchel, Anna, Eastgate, Melissa, Pearson, Sally-Ann, Mallardo, Domenico, Ascierto, Paolo A., Massi, Daniela, Merelli, Barbara, Mandala, Mario, Wilmott, James S., Menzies, Alexander M., Leduc, Charles, Stagg, John, Routy, Bertrand, Long, Georgina V., Scolyer, Richard A., Bald, Tobias, Waddell, Nicola, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2020). Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clinical Cancer Research, 26 (14), 3671-3681. doi: 10.1158/1078-0432.ccr-19-3925

  • Chew, Hui Yi, De Lima, Priscila O., Gonzalez Cruz, Jazmina L., Banushi, Blerida, Echejoh, Godwins, Hu, Lingbo, Joseph, Shannon R., Lum, Benedict, Rae, James, O'Donnell, Jake S., Merida de Long, Lilia, Okano, Satomi, King, Brigid, Barry, Rachael, Moi, Davide, Mazzieri, Roberta, Thomas, Ranjeny, Souza-Fonseca-Guimaraes, Fernando, Foote, Matthew, McCluskey, Adam, Robinson, Phillip J., Frazer, Ian H., Saunders, Nicholas A., Parton, Robert G., Dolcetti, Riccardo, Cuff, Katharine, Martin, Jennifer H., Panizza, Benedict, Walpole, Euan ... Simpson, Fiona (2020). Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 180 (5), 895-914.e27. doi: 10.1016/j.cell.2020.02.019

  • O'Donnell, Jake S., Hoefsmit, Esmee P., Smyth, Mark J., Blank, Christian U. and Teng, Michele W.L. (2019). The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clinical Cancer Research, 25 (19), 5743-5751. doi: 10.1158/1078-0432.CCR-18-2641

  • O’Donnell, Jake S., Teng, Michele W. L. and Smyth, Mark J. (2019). Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 16 (3), 151-167. doi: 10.1038/s41571-018-0142-8

  • Liu, Jing, O’Donnell, Jake S., Yan, Juming, Madore, Jason, Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2019). Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. OncoImmunology, 8 (5) e1581530, 1-12. doi: 10.1080/2162402X.2019.1581530

  • Ahern, Elizabeth, Harjunpää, Heidi, O'Donnell, Jake S., Allen, Stacey, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2018). RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. OncoImmunology, 7 (6) e1431088, e1431088. doi: 10.1080/2162402X.2018.1431088

  • Liu, Jing, Rozeman, Elisa A., O’Donnell, Jake S., Allen, Stacey, Fanchi, Lorenzo, Smyth, Mark J., Blank, Christian U. and Teng, Michele W. L. (2018). Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. OncoImmunology, 8 (2) e1546068, 1-10. doi: 10.1080/2162402X.2018.1546068

  • Glodde, Nicole, Bald, Tobias, van den Boorn-Konijnenberg, Debby, Nakamura, Kyohei, O'Donnell, Jake S., Szczepanski, Sabrina, Brandes, Maria, Eickhoff, Sarah, Das, Indrajit, Shridhar, Naveen, Hinze, Daniel, Rogava, Meri, van der Sluis, Tetje C., Ruotsalainen, Janne J., Gaffal, Evelyn, Landsberg, Jennifer, Ludwig, Kerstin U., Wilhelm, Christoph, Riek-Burchardt, Monika, Müller, Andreas J., Gebhardt, Christoffer, Scolyer, Richard A., Long, Georgina V., Janzen, Viktor, Teng, Michele W. L., Kastenmüller, Wolfgang, Mazzone, Massimiliano, Smyth, Mark J., Tüting, Thomas and Hölzel, Michael (2017). Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 47 (4), 789-802. doi: 10.1016/j.immuni.2017.09.012

  • O'Donnell, Jake S., Massi, Daniela, Teng, Michele W. L. and Mandala, Mario (2017). PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Seminars in Cancer Biology, 48, 91-103. doi: 10.1016/j.semcancer.2017.04.015

  • O'Donnell, Jake S., Long, Georgina V., Scolyer, Richard A., Teng, Michele W. L. and Smyth, Mark J. (2017). Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Reviews, 52, 71-81. doi: 10.1016/j.ctrv.2016.11.007

  • Liu, Jing, Blake, Stephen J., Yong, Michelle C. R., Harjunpaa, Heidi, Ngiow, Shin Foong, Takeda, Kazuyoshi, Young, Arabella, O'Donnell, Jake S., Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2016). Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discovery, 6 (12), 1382-1399. doi: 10.1158/2159-8290.CD-16-0577

  • O'Donnell, Jake S., Smyth, Mark J. and Teng, Michele W. L. (2016). Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. Genome Medicine, 8 (1) 111, 1-3. doi: 10.1186/s13073-016-0365-1

  • Pera, Elena, Kaemmerer, Elke, Milevskiy, Michael J. G., Yapa, Kunsala T. D. S., O'Donnell, Jake S., Brown, Melissa A., Simpson, Fiona, Peters, Amelia A., Roberts-Thomson, Sarah J. and Monteith, Gregory R. (2016). The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer. Cancer Cell International, 16 (24) 24, 24. doi: 10.1186/s12935-016-0299-0

Conference Publication

  • de Oliveira, A. Lepletier, Madore, J., O'donnell, S., Johnston, R. L., Eastgate, M., Mallardo, D., Ascierto, P. A., Massi, D., Merelli, B., Mandala, M., Wilmott, J. S., Bald, T., Stagg, J., Routy, B., Long, G. V., Scolyer, R. A., Waddell, N., Dougall, W. C., Teng, M. W. L. and Smyth, M. (2019). Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+T cells (PD1tR) driven by tumour CD155. Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11-14 December 2019. Oxford, United Kingdom: Oxford University Press.

  • Kaemmerer, Elke, Pere, Elena, Peters, Amelia A., Yapa, Kunsala T. D. S., Simpson, Fiona, O'Donnell, Jake, Roberts-Thomson, Sarah J. and Monteith, Gregory R. (2015). Calcium signalling and the acquisition of trastuzumab resistance in HER2 positive breast cancer cells. APSA ASCEPT Joint Scientific Meeting 2015, Hobart, TAS Australia, 29 November - 2 December 2015.